Eli Lilly agrees to pay $57 a share for Morphic, a 79% premium to the stock’s closing price of $31.84 on Friday.
Eli Lilly has agreed to buy biopharmaceutical company Morphic Holding for $3.2 billion in a deal that bolsters the ...
Eli Lilly on Monday announced a $3.2 billion all-cash deal to purchase Morphic and its pipeline of oral integrin therapies in ...
The deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel disease.
Eli Lilly says it will acquire a Waltham-based drug company that's working on a treatment for inflammatory bowel disease.
Eli Lilly & Co. has announced the acquisition of Morphic Holding Inc., a US-based biotech company specializing in treatments ...
Eli Lilly N/A will acquire Morphic Holding N/A for $3.2-billion in cash, the companies said on Monday, giving the U.S.
Eli Lilly agreed to buy Morphic Holding for $3.2 billion in cash, the companies said on Monday, beefing up its portfolio of ...
Leerink Partners analyst Thomas Smith has maintained their bullish stance on MORF stock, giving a Buy rating on July 8. Thomas Smith has given ...
It was a mating dance that lasted more than three years. At the end, Eli Lilly and Co. wound up buying a Massachusetts-based ...
Eli Lilly said Monday it will acquire Morphic Holding, a biotech developing a treatment for inflammatory bowel disease.
Eli Lilly will acquire Morphic Holding for $3.2 billion, the companies said on Monday, giving the U.S. drugmaker access to an ...